Quanterix Co. (NASDAQ:QTRX – Get Free Report) Director William P. Donnelly bought 93,113 shares of the firm’s stock in a transaction on Friday, June 6th. The stock was bought at an average cost of $5.44 per share, for a total transaction of $506,534.72. Following the transaction, the director now directly owns 139,094 shares of the company’s stock, valued at $756,671.36. The trade was a 202.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Quanterix Stock Performance
Shares of QTRX stock traded down $0.31 during midday trading on Monday, hitting $5.06. 785,234 shares of the company were exchanged, compared to its average volume of 579,955. Quanterix Co. has a 52 week low of $4.05 and a 52 week high of $19.18. The firm’s 50 day moving average price is $5.31 and its two-hundred day moving average price is $7.92. The firm has a market capitalization of $196.47 million, a P/E ratio of -4.77 and a beta of 1.05.
Quanterix (NASDAQ:QTRX – Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.16. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The company had revenue of $30.33 million during the quarter, compared to analysts’ expectations of $28.27 million. Analysts expect that Quanterix Co. will post -0.98 EPS for the current year.
Hedge Funds Weigh In On Quanterix
Analyst Ratings Changes
A number of research analysts have recently issued reports on the company. Leerink Partners reissued a “market perform” rating and issued a $8.00 target price (down previously from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. Scotiabank reiterated an “outperform” rating on shares of Quanterix in a report on Tuesday, March 25th. Canaccord Genuity Group dropped their price objective on Quanterix from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. Leerink Partnrs cut Quanterix from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 30th. Finally, Wall Street Zen cut Quanterix from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Quanterix has an average rating of “Hold” and a consensus price target of $15.60.
Read Our Latest Research Report on QTRX
About Quanterix
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Recommended Stories
- Five stocks we like better than Quanterix
- How to buy stock: A step-by-step guide for beginners
- Palantir Stock Holds Support, Despite Political Backlash
- How to Calculate Options Profits
- 3 Tightly-Held Growth Stocks Set Up for Short Squeezes
- Trading Halts Explained
- Science Applications International Is a Wicked Hot Buy in June
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.